Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Institut Biochimique SA

www.ibsa-ch.com

Latest From Zeneca Pharmaceuticals

Appointments: Gilead, Biogen, Nordic Nanovector, Neon Therapeutics, Achaogen and vasopharm

This week's roundup includes executive appointments by Gilead Sciences, Nordic Nanovector, Mereo BioPharma, vasopharm and Rigontec. Biogen has also appointed two executives to its planned spin-off company, Bioverativ.

Appointments

Deals Update (09/2007)

A roundup of recent medtech strategic alliances, mergers & acquisitions and financings.
Medical Device

Further Consolidation in Anatomic Pathology

Dianon System's purchase in June of UroCor was hardly surprising, coming after three years of discussions between the two companies. The purchase of UroCor, a disease management company, will fortify Dianon's already strong franchise in urology clinical diagnostics testing. The deal, a stock-for-stock transaction valued at about $180 million, merges two complementary businesses, offering opportunities for synergies and leveraging of operations.
BioPharmaceutical Strategy

Accelerating Small Molecule Drug Discovery

Pharmaceutical companies face two giant risks; compound risk and target risk. So, despite an abundance of so-called validated targets emerging from genomics efforts, and novel high throughput tools for compound synthesis and screening that yield plenty of hits against each target, at the end of the day, pharmaceutical company productivity, as measured by approved drugs, remains low. Recently, several former big-pharma executives have founded private companies that hope to speed up the time it takes to come up with optimized small molecule leads. Each has staked out a particular niche where it thinks it can do better than big pharma at coming up with clinic-ready compounds. Kinetix Pharmaceuticals and Triad Pharmaceuticals hope to leverage their knowledge of particular gene families to come up with optimized leads; Enanta Pharmaceuticals hopes to morph peptides into drugs with a combinatorial approach to binding pharmacophores, and Sunesis hopes to tackle some of the targets that prove intractable for others, or in which only large molecules have been able to intervene. The new small molecule companies share a vision of drug discovery that is based on targets, rather than diseases.
BioPharmaceutical Strategy
See All

Company Information

  • Industry
  • Medical Devices
  • Pharmaceuticals
    • Drug Delivery
      • Transdermal
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Switzerland
  • Parent & Subsidiaries
  • Institut Biochimique SA
  • Senior Management
  • Contact Info
  • Institut Biochimique SA
    Phone: (41) 58 360 1000
    Via del piano
    P.O. Box 266 Pambio-Noranco, 6915
    Switzerland
Advertisement
Advertisement
UsernamePublicRestriction

Register